 |
|
Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen, MD, DMSc ;
Peter C. Gøtzsche, MD, DMSc
JAMA. 1999;282:1752-1759.
Meta-analyses may become biased if the reported data in the individual trials are biased and if overlap among trials cannot be identified. We describe the unanticipated problems we encountered in collecting data for a meta-analysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia. In 3 large trials that comprised 43% of the patients identified for the meta-analysis, results for amphotericin B were combined with results for nystatin in a "polyene" group. Because nystatin is recognized as an ineffective drug in these circumstances, this approach creates a bias in favor of fluconazole. Furthermore, 79% of the patients were randomized to receive oral amphotericin B, which is poorly absorbed and not an established treatment, in contrast to intravenous amphotericin B, which was administered in 4 of 5 placebo-controlled trials, or 86% of patients. It was unclear whether there was overlap among the "polyene" trials, and it is possible that results from single-center trials were included in multicenter trial reports. We were unable to obtain information to clarify these issues from the trial authors or the manufacturer of fluconazole. Two of 11 responding authors replied that the data were with the drug manufacturer and two indicated that they did not have access to their data because of change of affiliation. In the meta-analyses, fluconazole and amphotericin B (mostly given orally) had similar effects (13 trials), whereas nystatin was no better than placebo (3 trials). Since individual trials are rarely conclusive, investigators, institutions, and pharmaceutical companies should provide essential details about their work to ensure that meta-analyses can accurately reflect the studies conducted and that patients will realize maximum benefits from treatments. We recommend that investigators keep copies of their trial data to help facilitate accurate and unbiased meta-analyses.
Author Affiliations: The Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Improving the Conduct and Reporting of Clinical Trials
Hannelore Bernhardt, Helene Panzer, Lon S. Schneider, Elizabeth Wager, John A. Tumas, Elizabeth A. Field, N. Bradly Glazer, Gail Schulz, Leni Grossman, Helle Krogh Johansen, Peter C. Gøtzsche, and Drummond Rennie
JAMA. 2000;283(21):2787-2790.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Appendix: Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis
Helle Krogh Johansen and Peter C. Gøtzsche
JAMA. 1999;282(18):1756-1757.
EXTRACT
| FULL TEXT
Fair Conduct and Fair Reporting of Clinical Trials
Drummond Rennie
JAMA. 1999;282(18):1766-1768.
EXTRACT
| FULL TEXT
November 10, 1999
JAMA. 1999;282(18):1787-1788.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Trial Investigators and Their Prescribing Patterns: Another Dimension to the Relationship Between Physician Investigators and the Pharmaceutical Industry
Psaty and Rennie
JAMA 2006;295:2787-2790.
FULL TEXT
Misleading Statements in Industry-Sponsored Meta-Analysis of Itraconazole
Gotzsche and Johansen
JCO 2005;23:9428-9429.
FULL TEXT
Conflict of interest in psychiatry
Ahmer et al.
Psychiatr. Bull. 2005;29:302-304.
ABSTRACT
| FULL TEXT
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors
Chan and Altman
BMJ 2005;330:753.
ABSTRACT
| FULL TEXT
Implications of Pharmaceutical Industry Funding on Clinical Research
Lexchin
The Annals of Pharmacotherapy 2005;39:194-197.
ABSTRACT
| FULL TEXT
Itraconazole versus Fluconazole for Antifungal Prophylaxis
Mossad
ANN INTERN MED 2004;140:580-581.
FULL TEXT
Randomized clinical trials: What gets published, and when?
Hirsch
CMAJ 2004;170:481-483.
FULL TEXT
Registering Clinical Trials
Dickersin and Rennie
JAMA 2003;290:516-523.
ABSTRACT
| FULL TEXT
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin et al.
BMJ 2003;326:1167-1170.
ABSTRACT
| FULL TEXT
Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors
Yank and Barnes
J. Med. Ethics 2003;29:109-114.
ABSTRACT
| FULL TEXT
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman et al.
JAMA 2003;289:454-465.
ABSTRACT
| FULL TEXT
Screening for Postmenopausal Osteoporosis: A Review of the Evidence for the U.S. Preventive Services Task Force
Nelson et al.
ANN INTERN MED 2002;137:529-541.
ABSTRACT
| FULL TEXT
Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force
Humphrey et al.
ANN INTERN MED 2002;137:347-360.
ABSTRACT
| FULL TEXT
Early Toronto experience with new standards for industry-sponsored clinical research: a progress report
Naylor
CMAJ 2002;166:453-456.
FULL TEXT
In Search of the Magic Nutraceutical: Problems with Current Approaches
Heyland
J. Nutr. 2001;131:2591S-2595.
ABSTRACT
| FULL TEXT
Drug-Related Adverse Events: A Readers' Guide to Assessing Literature Reviews and Meta-analyses
Ross
Arch Intern Med 2001;161:1041-1046.
FULL TEXT
Improving the Conduct and Reporting of Clinical Trials
Bernhardt et al.
JAMA 2000;283:2787-2790.
FULL TEXT
Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry
Bodenheimer
NEJM 2000;342:1539-1544.
FULL TEXT
Fair Conduct and Fair Reporting of Clinical Trials
Rennie
JAMA 1999;282:1766-1768.
FULL TEXT
|
